BUZZ-Street View: New growth drivers show promise to boost Medtronic's revenue

Reuters

02-20

BUZZ-Street View: New growth drivers show promise to boost Medtronic's revenue

** Medtronic on Tuesday missed Wall Street estimates for third-quarter revenue due to lower purchases of its surgical devices by distributors, and said the problems would persist in the current quarter

PLETHORA OF CATALYSTS AT PLAY

** J.P. Morgan ("Neutral", PT: $95) says there are reasons to stay more positive into FY26 with growth in co's diabetes and heart device business, along with contribution from new products which are used for procedures such as renal denervation and pulsed field ablation

** RBC Capital markets ("Outperform", PT: $105) says MDT has "plethora of catalysts at play" including its surgical robot Hugo and expansion in its portfolio for cardiac devices, along with significant opportunity in renal denervation

** UBS ("Neutral", PT: $95) sees potential for continued improvement in diabetes segment

** Citi ("Neutral", PT: $92) says Medtronic is standing on the threshold of several new growth drivers that are starting to gain traction

(Reporting by Siddhi Mahatole)

((Siddhiprabhanjan.mahatole@thomsonreuters.com))

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2512846454"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2512846454\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2512846454?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-20 00:34","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2512846454","market":"us","top_or_hot":-1,"title":"BUZZ-Street View: New growth drivers show promise to boost Medtronic's revenue","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-Street View: New growth drivers show promise to boost Medtronic's revenue</title></head><body><p>** Medtronic <span>on Tuesday</span> missed Wall Street estimates for third-quarter revenue due to lower purchases of its surgical devices by distributors, and said the problems would persist in the current quarter</p><p>PLETHORA OF CATALYSTS AT PLAY</p><p>** J.P. Morgan (\"Neutral\", PT: $95) says there are reasons to stay more positive into FY26 with growth in co's diabetes and heart device business, along with contribution from new products which are used for procedures such as renal denervation and pulsed field ablation</p><p>** RBC Capital markets (\"Outperform\", PT: $105) says MDT has \"plethora of catalysts at play\" including its surgical robot Hugo and expansion in its portfolio for cardiac devices, along with significant opportunity in renal denervation</p><p>** UBS (\"Neutral\", PT: $95) sees potential for continued improvement in diabetes segment</p><p>** Citi (\"Neutral\", PT: $92) says Medtronic is standing on the threshold of several new growth drivers that are starting to gain traction</p><p> (Reporting by Siddhi Mahatole)</p><p> ((Siddhiprabhanjan.mahatole@thomsonreuters.com))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BUZZ-Street View: New growth drivers show promise to boost Medtronic's revenue</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBUZZ-Street View: New growth drivers show promise to boost Medtronic's revenue\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-02-20 00:34</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-Street View: New growth drivers show promise to boost Medtronic's revenue</title></head><body><p>** Medtronic <span>on Tuesday</span> missed Wall Street estimates for third-quarter revenue due to lower purchases of its surgical devices by distributors, and said the problems would persist in the current quarter</p><p>PLETHORA OF CATALYSTS AT PLAY</p><p>** J.P. Morgan (\"Neutral\", PT: $95) says there are reasons to stay more positive into FY26 with growth in co's diabetes and heart device business, along with contribution from new products which are used for procedures such as renal denervation and pulsed field ablation</p><p>** RBC Capital markets (\"Outperform\", PT: $105) says MDT has \"plethora of catalysts at play\" including its surgical robot Hugo and expansion in its portfolio for cardiac devices, along with significant opportunity in renal denervation</p><p>** UBS (\"Neutral\", PT: $95) sees potential for continued improvement in diabetes segment</p><p>** Citi (\"Neutral\", PT: $92) says Medtronic is standing on the threshold of several new growth drivers that are starting to gain traction</p><p> (Reporting by Siddhi Mahatole)</p><p> ((Siddhiprabhanjan.mahatole@thomsonreuters.com))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MDT","symbol_name":"美敦力","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250219:nL3N3PA0SA:1","article_id":"2512846454","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2512846454","pubTimestamp":1739982885,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BUZZ-Street View: New growth drivers show promise to boost Medtronic's revenue** Medtronic on Tuesday missed Wall Street estimates for third-quarter revenue due to lower purchases of its surgical devi","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"MDT":"美敦力"},"translate_title":"BUZZ-Street View：新的增长动力有望增加美敦力的收入","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MDT":0.9},"content_text":"BUZZ-Street View: New growth drivers show promise to boost Medtronic's revenue** Medtronic on Tuesday missed Wall Street estimates for third-quarter revenue due to lower purchases of its surgical devices by distributors, and said the problems would persist in the current quarterPLETHORA OF CATALYSTS AT PLAY** J.P. Morgan (\"Neutral\", PT: $95) says there are reasons to stay more positive into FY26 with growth in co's diabetes and heart device business, along with contribution from new products which are used for procedures such as renal denervation and pulsed field ablation** RBC Capital markets (\"Outperform\", PT: $105) says MDT has \"plethora of catalysts at play\" including its surgical robot Hugo and expansion in its portfolio for cardiac devices, along with significant opportunity in renal denervation** UBS (\"Neutral\", PT: $95) sees potential for continued improvement in diabetes segment** Citi (\"Neutral\", PT: $92) says Medtronic is standing on the threshold of several new growth drivers that are starting to gain traction (Reporting by Siddhi Mahatole) ((Siddhiprabhanjan.mahatole@thomsonreuters.com))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1}}}